CLL-321 Trial Efficacy and Safety Results Analysis

Dr. Xavier asks about compelling efficacy signals from the CLL-321 trial, requesting Dr. Shameem to walk through trial highlights. The trial randomized patients with prior covalent BTKi exposure to pirtobrutinib versus investigator's choice (bendamustine or idelalisib globally, though idelalisib access varies by region). Dr. Shameem emphasizes that 100% of patients received prior covalent BTKis, with majority experiencing progression though some had intolerance issues, representing relevant clinical scenarios.

More than 50% of patients had prior BCL-2i therapy, with many heavily pretreated. Updated analysis demonstrated progression-free survival (PFS) of approximately 14 months with pirtobrutinib versus 8.7 months with investigator's choice. Subgroup analyses based on prior venetoclax exposure versus venetoclax-naïve status showed sustained PFS benefits. The trial included substantial numbers of patients with TP53 aberrations or del(17p) (over 40%), with subgroup analysis demonstrating PFS benefit with hazard ratio around 0.5.

Time to next treatment represented an important clinical endpoint, with median time to next therapy of 24 months for pirtobrutinib versus 10.9 months for investigator's choice. Subgroup analysis for venetoclax-naïve patients showed time to next therapy approaching 30 months (29 months). These PFS and time to next treatment results provide compelling efficacy evidence informing clinical practice decisions.

Regarding safety considerations in the context of prior BTKi exposure, Dr. Shameem notes no new safety signals for pirtobrutinib in this phase 3 trial, with majority of adverse reactions being low-grade. Cardiac toxicity rates were notably favorable, with atrial fibrillation incidence of 3% and hypertension 7%. Although cross-trial comparisons should be avoided, considering existing BTKi knowledge, these represent lower cardiac toxicity incidence rates despite heavily pretreated patient populations with prior covalent BTKi exposure.

Dr. Xavier confirms optional crossover was allowed in the trial, making the Kaplan-Meier curve differences more impressive given this design feature that typically makes survival benefit demonstration more challenging in clinical trials.